Biotech News

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics (TPST)Tempest Therapeutics2026-05-06 11:00 ESTClinical readout

100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1) Favorable safety profile with no Grade > 3 CRS or ICANS in REDEEM-1 trial evaluating TPST-2003 in

Open original release

Related news

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

IMTXImmatics2026-05-30 12:00 EST

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

IMTXImmatics2026-05-31 13:00 EST

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

COGTCogent Biosciences2026-05-30 12:00 EST

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

BNTXBioNTech2026-05-22 09:00 EST

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

View all latest news

Tempest Therapeutics

Tempest Therapeutics is an oncology company focused on small molecules and immunotherapy combinations for difficult cancers. Its investment case is driven by the idea that combination strategies can unlock differentiated responses in solid tumors.

Recent company news

TPSTTempest Therapeutics2026-05-29 12:00 EST

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

TPSTTempest Therapeutics2026-05-06 11:00 EST

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-29 12:00 EST

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-22 12:00 EST

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Stock data

Close: 0.93 USD
Market cap: 19.4M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States